What is Nabsys?
Headquartered in Providence, Rhode Island, Nabsys is dedicated to advancing the understanding of complex disease states through the routine, accurate, and cost-effective analysis of genomic structural variation. By leveraging a sophisticated interdisciplinary team of scientists and engineers, the company aims to significantly increase diagnostic yield and improve patient outcomes. Nabsys occupies a critical niche in the biotechnology landscape, providing the tools necessary to bridge the gap between raw genomic data and actionable clinical insights, thereby positioning itself as an essential partner for healthcare providers and research institutions globally.
How much funding has Nabsys raised?
Nabsys has raised a total of $117.5M across 13 funding rounds:
Series C
$10M
Debt
$4.7M
Grant
$244K
Private Equity
$25.5M
Private Equity
$6M
Other Financing Round
$21M
Debt
$150K
Private Equity
$38M
Series C (2011): $10M, investors not publicly disclosed
Debt (2012): $4.7M, investors not publicly disclosed
Grant (2012): $244K supported by Internal Revenue Service
Private Equity (2014): $25.5M featuring Rose Ventures, Inc and Bay City Capital
Private Equity (2016): $6M backed by Jilin Zixin Pharmaceutical Industrial Co., Ltd
Other Financing Round (2019): $21M with participation from Hitachi High-Technologies Corporation
Debt (2020): $150K led by PPP
Private Equity (2022): $38M supported by Hitachi High-Tech Corporation
Key Investors in Nabsys
Hitachi High-Tech Corporation
A global leader in scientific instruments and industrial systems, Hitachi High-Tech provides the technological infrastructure and strategic backing necessary for scaling complex diagnostic platforms.
Bay City Capital
A specialized venture capital firm with a deep focus on the life sciences sector, known for supporting companies through critical milestones including FDA approvals and therapeutic advancements.
Slater Technology Fund
An evergreen, not-for-profit seed fund that serves as a cornerstone for technology venture development in Rhode Island, focusing on high-impact economic and scientific growth.
What's next for Nabsys?
With the infusion of $38M, Nabsys is well-positioned to scale its operational capabilities and accelerate the commercial deployment of its genomic analysis solutions. The company's strategic roadmap likely involves expanding its market footprint, refining its diagnostic throughput, and deepening its collaborative efforts with global industrial partners. As the demand for high-resolution genomic data continues to rise, Nabsys is poised to leverage its recent capital injection to solidify its competitive advantage, drive further innovation in structural genomics, and ultimately transform the standard of care for patients requiring precise genetic diagnostics.
See full Nabsys company page
